ERBB2 and breast carcinoma: With the development of new HER2-targeting drugs and the expanding options for targeting the HER2 pathway in breast cancer and other solid tumors [11–14], accurate and reliable HER2 testing to ensure that the right patients receive the right treatment is critical.